Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about liquid-to-solid transition: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| neurodegenerative pathology | causes | mechanism | 0.70 |
| ALS/FTD | risk_factor_for | disease | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| FUS mutations | causes | gene | 0.90 |
| stress granules | causes | process | 0.90 |
| aggregation-prone proteins (TDP-43, FUS) | causes | protein | 0.70 |
| K63-ubiquitination | prevents | pathway | 0.70 |
| TRIM21 | prevents | protein | 0.70 |
| G3BP1 | causes | protein | 0.70 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Ubiquitin-Mediated Liquid-to-Solid Transition Prevention | 0.730 | neurodegeneration | How does TRIM21-mediated K63 ubiquitinat |
| Liquid-to-Solid Transition Pathology Reveals Granule Weak Po | 0.712 | neurodegeneration | What determines the specificity of RNA-p |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.712
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.730
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Proof of concept: targeted protein degradation of the stress granules component [PMID:41586493] | Unknown | Antimicrobial agents and chemo | 2026 | 0 |
| Stress granules: Guardians of cellular health and triggers of disease. [PMID:39995077] | ["Desai M", "Gulati K", "Agrawal M", "Gh | Neural regeneration research | 2026 | 0 |
| Implications of virus-induced stress granules in tauopathies. [PMID:41673769] | Sharma S, Vandenakker A, Cortés-Pérez C, | Translational neurodegeneratio | 2026 | 0 |
| Stress granules: Guardians of cellular health and triggers of disease. [PMID:39995077] | Desai M, Gulati K, Agrawal M, Ghumra S, | Neural Regen Res | 2026 | 0 |
| Uridine analogs prevent stress granule formation, not by blocking PKR recognitio [PMID:41571440] | Ihn SJ, Jiang E, Kejiou NS, Wang YE, Far | RNA | 2026 | 0 |
| Proof of concept: targeted protein degradation of the stress granules component [PMID:41586493] | Echavarria-Consuegra L, Goodfellow I | Antimicrob Agents Chemother | 2026 | 0 |
| Atg5/Autophagy inactivation in mouse bone microenvironment promotes tumor develo [PMID:41612597] | Trojani MC, Nollet M, Camuzard O, Santuc | Autophagy | 2026 | 0 |
| High expression of G3BP1 is associated with poor prognosis in breast invasive ca [PMID:41635545] | Li J, Zong Z, Shen J, Wang J, Zhou X et | Oncol Lett | 2026 | 0 |
| Implications of virus-induced stress granules in tauopathies. [PMID:41673769] | Sharma S, Vandenakker A, Cortés-Pérez C, | Transl Neurodegener | 2026 | 0 |
| Dysregulated miRNAs and downstream gene expression associated with poor treatmen [PMID:41694232] | Yu SC, Wang YC, Lin HP, Jen YW, Hwang TJ | Brain Behav Immun Health | 2026 | 0 |
| Pharmacological modulation of stress granules via G3BP1/2: A pathway to treat ca [PMID:41924133] | Yang J, Gao F | Front Pharmacol | 2026 | 0 |
| Stress granules at the crossroads of retroviral replication and antiviral immuni [PMID:41931190] | Akbarin MM, Farjami Z, Álvarez HR | Mol Biol Rep | 2026 | 0 |
| Targeting G3BP1-Mediated Stress Granules to Suppress SARS-CoV-2 Replication. [PMID:41960678] | Aromokeye R, Kuang L, Ackerman-Berrier M | ACS Infect Dis | 2026 | 0 |
| The neuroprotective effect of Cucurbitacin B against Aβ and tau toxicities requi [PMID:42012542] | Tu X, Fang M, Yan Y, Liu Y, Yu J et al. | Biogerontology | 2026 | 0 |
| Pharmacological modulation of stress granules via G3BP1/2: A pathway to treat ca [PMID:41924133] | Yang J, Gao F | Frontiers in pharmacology | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.58 · 2026-04-27
closed · Rounds: 4 · Score: 0.79 · 2026-04-21
closed · Rounds: 4 · Score: 0.76 · 2026-04-21
Hypotheses and analyses mentioning liquid-to-solid transition in their description or question text
No additional research found